checkAd

    SNOA (Mkap $22 M) Cash $12.6 M) Etliche Produkte am Markt + weitere Produkteinführungen (Seite 12)

    eröffnet am 11.08.17 14:10:41 von
    neuester Beitrag 10.06.23 11:37:12 von
    Beiträge: 176
    ID: 1.259.169
    Aufrufe heute: 0
    Gesamt: 31.207
    Aktive User: 0


    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 12
    • 18

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 25.11.17 12:35:10
      Beitrag Nr. 66 ()
      CFO Robert E. Miller hat sich kürzlich mit 2000 Aktien zugedeckt..

      https://www.marketbeat.com/stocks/NASDAQ/SNOA/?RegistrationC…
      1 Antwort
      Avatar
      schrieb am 16.11.17 19:11:39
      Beitrag Nr. 65 ()
      Step by step...
      Aus dem transcript:

      "On the brand-building front, I draw your attention to alevicyn.com. It’s a micro site launched two weeks ago that adds support to the success of our best-in-class dermatology sales efforts. This site provides a specific brand promise on our most strategic product line to our most strategic customers, dermatologists who treat atopic dermatitis patients."

      http://alevicyn.com/" target="_blank" rel="nofollow ugc noopener">http://alevicyn.com/

      Weiter so! :)
      Avatar
      schrieb am 16.11.17 16:57:34
      Beitrag Nr. 64 ()
      Antwort auf Beitrag Nr.: 56.198.970 von Danny767 am 16.11.17 14:10:32 well, not bad............

      dann sollte es mal in Kürze nachhaltig nach oben gehen.

      Ich kaufe zu

      M.
      Avatar
      schrieb am 16.11.17 14:10:32
      Beitrag Nr. 63 ()
      Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language

      PETALUMA, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded claim for the company’s signature dermatology product, Alevicyn™ Dermal Spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms.

      “This important FDA milestone further validates Alevicyn’s antimicrobial activity against clinically relevant microorganisms and provides additional on-label evidence of patient benefits,” said Jeff Day, president of Sonoma Pharmaceutical’s dermatology division. “These new claims differentiate Alevicyn from topical steroids and should help propel our sales growth even faster as a strong alternative to those older products.”

      Alevicyn (www.alevicyn.com) products, available via prescription, provide dermatologists with a safe and clinically proven approach to management of atopic dermatitis without the side effects of topical steroids and resistance issues associated with the overuse of antibiotics. In addition, the Alevicyn products are used during and post-treatment on skin cancer surgical procedures. Over the last three years, there have been over 61,000 prescriptions filled for the Alevicyn family of products, valued at over $7.5 million. For more information regarding Alevicyn visit www.alevicyn.com.

      About the Global Dermatology Market
      According to BCC Research, skin conditions are among the most common health problems in most national populations, collectively exceeding the prevalence of conditions such as obesity, hypertension and cancer. The considerable costs of skin diseases include physician visits, hospital care, prescription drugs and over-the-counter products for treating or managing these conditions, as well as indirect costs due to productivity losses.

      The global market for skin disease treatment technologies is estimated to reach $20.4 billion in 2020. The U.S market is the largest segment and should reach $8.6 billion in 2020. The BRIC (Brazil, Russia, India, China) countries are the fastest growing region of the global dermatology market and should total more than $4.6 billion by 2020.

      About Sonoma Pharmaceuticals, Inc.
      Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.

      Forward-Looking Statements
      Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

      Sonoma Pharmaceuticals®, Alevicyn™ and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

      Media and Investor Contact:

      Sonoma Pharmaceuticals, Inc.
      Dan McFadden
      VP of Public and Investor Relations
      (425) 753-2105
      dmcfadden@Sonomapharma.com
      1 Antwort
      Avatar
      schrieb am 11.11.17 13:53:33
      Beitrag Nr. 62 ()
      Hier gibt es das "Earnings Call Transcript":

      https://seekingalpha.com/article/4123588-sonoma-pharmaceutic…


      "Before I finish my comments, I’d like to address a frequent question we get from investors. Do you have enough cash to get the profitability? The answer is, yes. We believe that based on our long-range forecast, we have sufficient cash to get us to profitability. And we have a number of non-diluted backups, including an AR line and the exercise of conversion of our trading warrants. And as we’ve mentioned previously on these calls, one of our corporate goals continues to be to add institutional buy-and-hold shareholders."

      Biohero hat am Anfang der Vorstellung der Aktie auch darauf hingewiesen, dass Sonoma eine weitere FDA Zulassung erhalten hat, die aber wegen der Konkurrenz nicht öffentlich gemacht wurde (CT Order). Deshalb gibt es keine näheren Details zu dem Produkt. Auch das wurde in den FAQ besprochen.

      "And then last question. Just getting back to the unnamed FDA approval. Can you share with us whether that is going – is it something that will be executed by this sales force or not? I guess, is – if you can give us that answer."

      "That one I can answer. And the answer is, yes."

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 10.11.17 17:02:31
      Beitrag Nr. 61 ()
      Die Kurzfrist-Trader nehmen Ihre Profite mit. Dann kann es ja bald langsam aber stetig aufwärts gehen....Schönes WE!
      Avatar
      schrieb am 10.11.17 15:30:57
      Beitrag Nr. 60 ()
      Antwort auf Beitrag Nr.: 56.154.026 von MVAL am 10.11.17 15:27:03Und das Fact-Sheet:

      http://files.shareholder.com/downloads/OCLS/5143614327x0x231…

      So, jetzt ham wa alles :)
      Avatar
      schrieb am 10.11.17 15:27:03
      Beitrag Nr. 59 ()
      Antwort auf Beitrag Nr.: 56.153.972 von MVAL am 10.11.17 15:23:09
      Irgendwie hat es den Link zerschossen:
      http://files.shareholder.com/downloads/OCLS/5143614327x0x963…

      http://files.shareholder.com/downloads/ocls/5143614327x0x945…
      1 Antwort
      Avatar
      schrieb am 10.11.17 15:23:09
      Beitrag Nr. 58 ()
      Jetzt muss der Wert nur noch bekannter werden. Auf Ihub gerade mal 3 Follower.

      Hier das Fact- Sheet

      http://files.shareholder.com/downloads/OCLS/5143614327x0x231…
      " target="_blank" rel="nofollow ugc noopener">http://files.shareholder.com/downloads/OCLS/5143614327x0x231…


      "Driving to commercial EBITDAS breakeven without Dilution"

      Und die Präsentation zum 2. Quartal:


      http://files.shareholder.com/downloads/OCLS/5143614327x0x963488/2A8DE31D-86A2-4ACF-BEB3-ED57ABAF2C2F/SNOAResultsSupplemental110917FINALB.pdf
      2 Antworten
      Avatar
      schrieb am 10.11.17 14:48:07
      Beitrag Nr. 57 ()
      Die Burn-Rate wurde drastisch minimiert und das, obwohl neues Personal eingestellt wurde. D.h. mit dem Vertrieb läuft es immer besser. Gefällt mir sehr gut.

      - EBITDA loss reduced to $2.3 million
      - Cash on hand equals $10 Million

      Weiter so!
      • 1
      • 12
      • 18
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      +0,16
      +1,44
      -0,94
      +1,42
      -0,89
      -4,35
      +1,30
      -30,00
      -4,10
      +4,95
      28.03.24 · Accesswire · Sonoma Pharmaceuticals
      27.03.24 · Accesswire · Sonoma Pharmaceuticals
      13.11.23 · Accesswire · Sonoma Pharmaceuticals
      03.11.23 · Accesswire · Sonoma Pharmaceuticals
      26.10.23 · Accesswire · Sonoma Pharmaceuticals
      15.08.23 · Accesswire · Sonoma Pharmaceuticals
      10.08.23 · Accesswire · Sonoma Pharmaceuticals
      03.08.23 · Accesswire · Sonoma Pharmaceuticals
      22.06.23 · Accesswire · Sonoma Pharmaceuticals
      08.06.23 · Accesswire · Sonoma Pharmaceuticals
      SNOA (Mkap $22 M) Cash $12.6 M) Etliche Produkte am Markt + weitere Produkteinführungen